A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus in India

NCT05659537 on ClinicalTrials.gov · last registry update 2025-02-20

An unusually large phase 4: 212 participants, more than double the 75 typical for the stage. Completed 16 January 2024. dulaglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: COMPLETED
Phase: P4
Drug: dulaglutide
Trulicity
Sponsor: Eli Lilly and Company
Sponsor type: Industry
Enrollment: 212
Started: 2022-12-29
Primary completion: 2024-01-16 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Number of Participants With One or More Adverse Events (AEs) - Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Deaths

Conditions studied

Diabetes Mellitus, Type 2

Every field above is taken directly from the registry record. See all detected changes across the class, or the dulaglutide page for this molecule’s full trial and approval history.